drugset / Trial / NCT03468855
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.
Timeline
- Start
- 2018-03-19
- Primary completion
- 2019-10-16
- Completion
- 2019-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IFIDANCITINIB | Small molecule | 0.46 % | Topical |